OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
05 nov 2007 - 22:44
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus presents positive Phase IIa study results for Locteron in hepatitis C at AASLD conference
Bericht
OctoPlus N.V. (“OctoPlus”) (Euronext: OCTO), the drug delivery and development company, announces that full and complete results from its successful SELECT-1 Phase IIa clinical trial of Locteron™ for the treatment of chronic hepatitis C will be presented today at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
Viral kinetic modeling of the SELECT-1 results by Eva Herrmann, Ph.D. and Stefan Zeuzem, M.D. of Saarland University Hospital, Homburg/Saar, Germany, demonstrated a statistically significant dose response. The study results also showed that patients receiving Locteron experienced side effects that were less frequent and less severe than those previously reported in clinical trials for the currently marketed pegylated interferons and for a development-stage product, Albuferon®.
Datum laatste update: 27 juli 2024